Premium
P2‐009: DEVELOPMENT OF THE MUSCARINIC CHOLINERGIC PAM VU319 FOR COGNITIVE ENHANCEMENT: PHASE 1 TESTS OF SAFETY AND TARGET ENGAGEMENT
Author(s) -
Newhouse Paul A.,
Conley Alexander C.,
Key Alexandra P.,
Blackford Jennifer U.,
Lindsley Craig W.,
Conn Jeffrey,
Jones Carrie K.
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.1231
Subject(s) - tolerability , muscarinic acetylcholine receptor , neuroscience , cholinergic , long term potentiation , muscarinic acetylcholine receptor m1 , synaptic plasticity , pharmacology , medicine , acetylcholine , adverse effect , psychology , receptor
P2-009 DEVELOPMENT OF THE MUSCARINIC CHOLINERGIC PAM VU319 FOR COGNITIVE ENHANCEMENT: PHASE 1 TESTS OF SAFETYAND TARGET ENGAGEMENT Paul A. Newhouse, Alexander C. Conley, Alexandra P. Key, Jennifer U. Blackford, CraigW. Lindsley, Jeffrey Conn, Carrie K. Jones, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt University, Nashville, TN, USA. Contact e-mail: paul.newhouse@ vanderbilt.edu